CSL Ltd
ASX:CSL

Watchlist Manager
CSL Ltd Logo
CSL Ltd
ASX:CSL
Watchlist
Price: 243.71 AUD -0.91% Market Closed
Market Cap: 118B AUD

EV/EBITDA
Enterprise Value to EBITDA

17.3
Current
22.7
Median
4.7
Industry
Lower than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
17.3
=
Enterprise Value
130B AUD
/
EBITDA
4.9B USD
EBITDA Growth EV/EBITDA to Growth
AU
CSL Ltd
ASX:CSL
Average EV/EBITDA: 31.8
17.3
11%
1.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -690.7 N/A N/A
NL
argenx SE
XBRU:ARGX
126.7
727%
0.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
16
2-Years Forward
EV/EBITDA
14.5
3-Years Forward
EV/EBITDA
13